What are the latest news in the cell therapy market?
Download our beautiful pitch about the cell therapy market
In our cell therapy market deck, you will find everything you need to understand the market
The cell therapy market is moving fast, and this article tracks the latest and biggest news shaping the industry.
We constantly update this blog post so readers can follow new deals, approvals, launches, and company updates in one place.
The goal is simple: help investors and entrepreneurs understand what each cell therapy market update means without using heavy biotech language.
And if you want to better understand this new industry, you can download our pitch covering the cell therapy market.
Insights
- Three of the biggest cell therapy market stories were M&A deals, showing that large pharma companies still prefer buying strong platforms instead of building every CAR-T asset internally.
- Lilly made two in-vivo CAR-T acquisitions in less than three months, which suggests the cell therapy market is shifting toward simpler manufacturing models.
- Multiple myeloma remained one of the most active areas in the cell therapy market, with both Kelonia and Arcellx tied to BCMA or myeloma strategies.
- Solid tumors kept attracting attention, but most cell therapy market progress still came from early clinical, regulatory, or access milestones rather than broad commercial success.
- The cell therapy market is no longer only about approvals, because label updates, manufacturing partnerships, and real-world access can also create commercial value.
- Academic centers are becoming more important in the cell therapy market, as CU Anschutz showed with its campus-built AML CAR-T moving toward the clinic.
- Commercial cell therapy companies are still under pressure, as Autolus showed that sales guidance can rise while cost cuts remain necessary.
- Automation and in-vivo delivery both point to the same cell therapy market problem: today’s personalized manufacturing model is still too complex and expensive.
- China remains a key region for the cell therapy market, especially for solid-tumor CAR-T access models that may move faster than global launches.
This chart, featured in our cell therapy market deck, shows how Legend Biotech is winning in cell therapy
Summary table of the latest news in the cell therapy market
We define the cell therapy market as the market for cell-based medicinal products used as drugs to treat disease, including both approved products and major late-stage pipeline therapies.
We include living-cell products such as CAR-T, other engineered immune cells, and non-oncology cell-based drugs, along with their direct clinical use and revenue.
We exclude procedures like standard stem-cell transplants, simple minimally manipulated cell preparations used in surgery, and generic tools or equipment that are not specific to these therapies.
You can also read our detailed analysis to understand what are the quarterly updates in the cell therapy market.
| News | Category | Exact date | Source |
|---|---|---|---|
| Autolus cut jobs while keeping strong Aucatzyl guidance. | Restructuring | Apr. 30, 2026 | Markets Insider |
| Gilead completed the Arcellx buyout before anito-cel launch. | M&A | Apr. 28, 2026 | Kite Pharma |
| Verismo showed a CAR-T design meant to reduce relapse. | Breakthrough | Apr. 21, 2026 | PR Newswire |
| Lilly bought its second in-vivo CAR-T platform in 10 weeks. | M&A | Apr. 20, 2026 | Eli Lilly and Company |
| J&J said Carvykti remained a major growth driver. | Financial results | Apr. 14, 2026 | Johnson & Johnson |
| China prepared access to a rare solid-tumor CAR-T option. | Market expansions | Apr. 9, 2026 | PR Newswire |
| AvenCell dosed the first patient with a switchable allogeneic CAR-T. | Product launches | Apr. 2, 2026 | PR Newswire |
| CU Anschutz won FDA clearance for a campus-built AML CAR-T. | Product launches | Apr. 2, 2026 | PR Newswire |
| A2 Bio’s solid-tumor CAR-T received FDA Fast Track. | Regulations & Policies | Apr. 1, 2026 | A2 Biotherapeutics |
| Cellares and UW moved automated CAR-T manufacturing toward the clinic. | Partnerships | Feb. 18, 2026 | Cellares |
| Lilly acquired Orna to push CAR-T beyond cancer. | M&A | Feb. 9, 2026 | Eli Lilly and Company |
| Yescarta gained a cleaner FDA label for brain lymphoma patients. | Regulations & Policies | Feb. 6, 2026 | Gilead |
Latest news of the cell therapy market
Autolus cut jobs while keeping strong Aucatzyl guidance.
Restructuring
What happened?
Autolus announced a cost-cutting plan in the cell therapy market and said Autolus would reduce its workforce by about 13%. Autolus also kept 2026 Aucatzyl revenue guidance at $120 million to $135 million.
When was it?
Autolus announced the restructuring on April 30, 2026.
Why is it big news?
The news shows that even commercial cell therapy companies need stronger margins, not only growing sales.
Why should you care?
If you’re an investor in the cell therapy market, Autolus shows that revenue growth does not remove cash discipline risk.
If you’re an entrepreneur in the cell therapy market, Autolus is a reminder to design manufacturing and commercial efficiency early.
As this chart shows, and as featured in our cell therapy market deck, search interest in stem cell therapy has been rising steadily
Gilead completed the Arcellx buyout before anito-cel launch.
M&A
What happened?
Gilead and Kite completed the acquisition of Arcellx after announcing the deal earlier in 2026. The deal gives Gilead full control of anito-cel, a BCMA CAR-T for multiple myeloma, before a possible launch.
When was it?
Gilead completed the Arcellx acquisition on April 28, 2026.
Why is it big news?
The deal shows that large pharma companies still want late-stage CAR-T assets in the cell therapy market.
Why should you care?
If you’re an investor in the cell therapy market, the Arcellx deal shows that differentiated late-stage assets can still attract major buyers.
If you’re an entrepreneur in the cell therapy market, the Arcellx deal shows that strong clinical assets can become strategic targets before launch.
This chart, featured in our cell therapy market deck, compares the main business model options for cell therapy biotech companies
Verismo showed a CAR-T design meant to reduce relapse.
Breakthrough
What happened?
Verismo presented AACR 2026 data for SynKIR-310, a multi-chain KIR-CAR therapy. Verismo designed SynKIR-310 to improve durability and reduce T-cell exhaustion in B-cell malignancies.
When was it?
Verismo presented the data on April 21, 2026.
Why is it big news?
Relapse after CAR-T remains a major problem, so better durability could matter a lot in the cell therapy market.
Why should you care?
If you’re an investor in the cell therapy market, Verismo points to a clear area where next-generation CAR-T products can stand out.
If you’re an entrepreneur in the cell therapy market, Verismo shows that receptor design is still an open field for innovation.
This market map, featured in our cell therapy market deck, highlights top companies and startups in the cell therapy market
Lilly bought its second in-vivo CAR-T platform in 10 weeks.
M&A
What happened?
Lilly agreed to acquire Kelonia Therapeutics. Kelonia is working on in-vivo CAR-T, which aims to create CAR-T cells inside the patient instead of manufacturing the cells outside the body.
When was it?
Lilly announced the Kelonia acquisition on April 20, 2026.
Why is it big news?
The deal suggests that the next big cell therapy market wave may focus on simpler and more scalable CAR-T delivery.
Why should you care?
If you’re an investor in the cell therapy market, Lilly’s deal validates in-vivo CAR-T as a major strategic area.
If you’re an entrepreneur in the cell therapy market, Kelonia shows that platforms reducing manufacturing complexity can attract large buyers.
This chart, featured in our cell therapy market deck, shows how market revenue is split across customer segments in the cell therapy market
J&J said Carvykti remained a major growth driver.
Financial results
What happened?
Johnson & Johnson reported Q1 2026 results and named Carvykti among the oncology products supporting Innovative Medicine growth. Carvykti is an approved CAR-T therapy for multiple myeloma.
When was it?
Johnson & Johnson reported the Q1 update on April 14, 2026.
Why is it big news?
Carvykti shows that approved cell therapy products can become meaningful revenue drivers for large pharma companies.
Why should you care?
If you’re an investor in the cell therapy market, Carvykti helps prove that cell therapy can move beyond science projects into real commercial products.
If you’re an entrepreneur in the cell therapy market, Carvykti creates room for services, diagnostics, manufacturing tools, and follow-on therapies.
This chart, featured in our cell therapy market deck, shows annual VC investment in cell therapy startups
China prepared access to a rare solid-tumor CAR-T option.
Market expansions
What happened?
Jiahui said a CAR-T therapy for advanced gastrointestinal cancers would become available in China in the first half of 2026. Solid tumors remain one of the hardest areas for CAR-T in the cell therapy market.
When was it?
Jiahui shared the update on April 9, 2026.
Why is it big news?
A workable CAR-T option for solid tumors could greatly expand the cell therapy market beyond blood cancers.
Why should you care?
If you’re an investor in the cell therapy market, China remains an important region for watching new access models.
If you’re an entrepreneur in the cell therapy market, regional launch paths may create faster ways to test demand and delivery models.
This chart, featured in our cell therapy market deck, shows annual funding in cell therapy startups
AvenCell dosed the first patient with a switchable allogeneic CAR-T.
Product launches
What happened?
AvenCell dosed the first patient in a Phase 1 study of AVC-203. AVC-203 is an off-the-shelf, CRISPR-engineered CAR-T therapy that targets CD19 and CD20 and includes switchable control.
When was it?
AvenCell announced the first patient dose on April 2, 2026.
Why is it big news?
AvenCell combines three important cell therapy market ideas: off-the-shelf cells, dual targeting, and added safety control.
Why should you care?
If you’re an investor in the cell therapy market, off-the-shelf CAR-T could improve access and margins if clinical results are strong.
If you’re an entrepreneur in the cell therapy market, safety-control features may become important for next-generation cell therapy design.
In our cell therapy market deck, we tell you what to focus on
CU Anschutz won FDA clearance for a campus-built AML CAR-T.
Product launches
What happened?
CU Anschutz received FDA IND clearance for a CD64 CAR-T for relapsed or refractory acute myeloid leukemia. The first Phase 1 study is expected to begin in summer 2026.
When was it?
CU Anschutz announced the FDA clearance on April 2, 2026.
Why is it big news?
The update shows that academic manufacturing centers can move serious cell therapy market programs toward human trials.
Why should you care?
If you’re an investor in the cell therapy market, academic centers can become strong sources of translational assets.
If you’re an entrepreneur in the cell therapy market, university infrastructure can help accelerate early clinical development.
In our cell therapy market deck, we identify pain points entrepreneurs should prioritize
A2 Bio’s solid-tumor CAR-T received FDA Fast Track.
Regulations & Policies
What happened?
FDA granted Fast Track designation to A2B543 from A2 Biotherapeutics. A2B543 is a logic-gated CAR-T therapy for certain solid tumors.
When was it?
A2 Biotherapeutics announced the Fast Track designation on April 1, 2026.
Why is it big news?
Fast Track can help speed development and review for serious diseases, which matters in the difficult solid-tumor CAR-T field.
Why should you care?
If you’re an investor in the cell therapy market, regulatory momentum can reduce some development uncertainty.
If you’re an entrepreneur in the cell therapy market, smarter targeting systems remain a key path into solid tumors.
In our cell therapy market deck, we dentify risks investors and builders need to be aware of
Cellares and UW moved automated CAR-T manufacturing toward the clinic.
Partnerships
What happened?
Cellares and the University of Wisconsin expanded their partnership. The partnership supports clinical production and regulatory work for a CRISPR-edited GD2 CAR-T for solid tumors.
When was it?
Cellares announced the expanded partnership on February 18, 2026.
Why is it big news?
Manufacturing remains one of the largest bottlenecks in the cell therapy market, so automation can change cost and speed.
Why should you care?
If you’re an investor in the cell therapy market, better manufacturing can improve the economics of CAR-T programs.
If you’re an entrepreneur in the cell therapy market, process innovation can be as valuable as biology.
In our cell therapy market deck, we ensure you have the latest information
Lilly acquired Orna to push CAR-T beyond cancer.
M&A
What happened?
Lilly agreed to acquire Orna Therapeutics. Orna’s in-vivo CAR-T pipeline focuses on resetting immune cells, including programs for autoimmune disease.
When was it?
Lilly announced the Orna acquisition on February 9, 2026.
Why is it big news?
The deal shows that the cell therapy market is moving beyond cancer and into chronic immune diseases.
Why should you care?
If you’re an investor in the cell therapy market, autoimmune CAR-T could become larger than rare blood cancer use cases.
If you’re an entrepreneur in the cell therapy market, non-oncology cell therapy is now a serious company-building opportunity.
In our cell therapy market deck, we like to quantify things to make things easier to understand
Yescarta gained a cleaner FDA label for brain lymphoma patients.
Regulations & Policies
What happened?
FDA removed a previous limitation from Yescarta’s label for relapsed or refractory primary central nervous system lymphoma. Gilead said Yescarta is the only CAR-T for relapsed or refractory large B-cell lymphoma with that limitation removed.
When was it?
Gilead announced the FDA label update on February 6, 2026.
Why is it big news?
A label update can quickly improve physician confidence and access for an approved cell therapy market product.
Why should you care?
If you’re an investor in the cell therapy market, mature CAR-T products can still grow through label improvements.
If you’re an entrepreneur in the cell therapy market, real-world safety evidence can create commercial value after approval.
Related blog posts
- The latest progress in the cell therapy market
- How strong is fundraising in the cell therapy market right now?
- What is the true size of the cell therapy market?
- How funding activity has evolved in the cell therapy market
- What are the key fundraising trends in the cell therapy market?
- A complete list of funding deals in the cell therapy market
- A complete list of business models in the cell therapy market
- Which companies have raised the most funding in the cell therapy market?
- Which companies are the most valued in the cell therapy market?
